menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Roivant Announces Resignation and Replacement of Arbutus Board

    GLOBENEWSWIRE

    Roivant Reports Financial Results for Q3 Ended December 31, 2024

    GLOBENEWSWIRE

    Moderna picks Merck KGaA, Roivant alum as marketing chief

    FIERCE PHARMA

    Roivant to Report Financial Results for the Q3 Dec 31

    GLOBENEWSWIRE

    Roivant to stop lung disease drug development after trial failure

    REUTERS

    Roivant`s Results from Namilumab Ph 2 Pulmonary Sarcoidosis Study

    GLOBENEWSWIRE

    Kinevant`s Results from Namilumab Ph 2 in Pulmonary Sarcoidosis

    GLOBENEWSWIRE

    Roivant Reports Financial Results for the Q2 Ended September 30

    GLOBENEWSWIRE

    Roivant to Report Q2 Results and Update on Nov 12, 2024

    GLOBENEWSWIRE

    Organon Acquires Dermavant, Including VTAMA® (tapinarof) Cream

    #N/A

    Organon pays up to $1.2B to acquire Dermavant and its steroid-free cream Vtama

    REUTERS

    Roivant unveils new ‘vant’ to take forward Bayer’s inhaled hypertension med

    BIOSPACE

    Roivant Unveils New Pipeline Program Mosliciguat

    GLOBENEWSWIRE

    Pulmovant Presents Mosliciguat Phase 1b Data At ERS Congress

    GLOBENEWSWIRE

    Roivant Provides Update on Graves’ Disease Development Program

    GLOBENEWSWIRE

    Roivant Reports Q1 2025 Financial Results And Business Update

    GLOBENEWSWIRE

    Roivant To Report Q1 2024 Results On August 8

    GLOBENEWSWIRE

    Roivant Reports Fiscal Year 2024 Results And Business Update

    GLOBENEWSWIRE

    Roivant To Report Q4, FY 2024 Results, Business Update May 30

    GLOBENEWSWIRE

    Moderna shares fall after judge sides with Arbutus in patent fight

    REUTERS

    Roivant`s anti-inflammatory drug shows promise in mid-stage study

    REUTERS

    Roivant launches $1.5 billion share buyback program

    PRESS RELEASE

    Roivant`s Hemavant bet winds down after cutting ex-Eisai drug

    FIERCE BIOTECH

    Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023

    GLOBENEWSWIRE

    Roivant to Report Financial Results for the Q3 Ended December 31, 2023

    GLOBENEWSWIRE

    Vivek Ramaswamy gives up presidential bid, no plans to return to Roivant

    ENDPTS

    JPM24: Roivant CEO has ‘pangs of regret’ for letting Telavant go

    FIERCE BIOTECH

    JPM24, Day 3: Gene editors talk BD; Roivant has cash to spend

    FIERCE BIOTECH

    Roivant Reports Positive Phase 2 Results for Batoclimab in Graves™ Disease

    GLOBENEWSWIRE

    Roche Completes Acquisition of Telavant from Roivant

    GLOBENEWSWIRE

    Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results

    GLOBENEWSWIRE

    Roivant Sciences` lupus drug fails to reduce symptoms in mid-stage study

    REUTERS

    Roivant Reports Financial Results for the Second Quarter Ended September 30

    GLOBENEWSWIRE

    Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

    GLOBENEWSWIRE

    Roivant to Report Financial Results for Second Quarter Ended September 30, 2023

    GLOBENEWSWIRE

    Roche buys Roivant`s bowel disease drug for $7.1 billion

    REUTERS

    Roivant FcRn inhibitor avoids cholesterol problem, shares spike

    FIERCE BIOTECH

    Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD

    GLOBENEWSWIRE

    Roivant Announces Completion of Redemption of its Outstanding Warrants

    GLOBENEWSWIRE

    Roivant Announces Redemption Fair Market Value with Redemption of Warrants

    GLOBENEWSWIRE

    Roivant Reports Financial Results for the First Quarter Ended June 30, 2023

    GLOBENEWSWIRE

    Roivant CEO hints at more deals shaping up as key Immunovant data loom

    ENDPTS

    Roivant to Report Financial Results for the Quarter Ended June 30, 2023

    GLOBENEWSWIRE

    Roivant Announces Redemption of Outstanding Warrants

    GLOBENEWSWIRE

    Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn™s Disease

    GLOBENEWSWIRE

    Roivant in talks to sell bowel disease drug to Roche in over $7 bln deal

    REUTERS

    Roivant Reports Financial Results for the 4Q and Fiscal Year Ended March 31

    GLOBENEWSWIRE

    Roivant to Report Financial Results for Q4 and Fiscal Year Ended March 31

    GLOBENEWSWIRE

    Roivant to Host Investor Call at 8:00 AM ET Thursday, June 22 to Review Results

    GLOBENEWSWIRE

    Roivant Reports Positive Topline Results from ADORING 1, Ph 3 Trial

    GLOBENEWSWIRE

    Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships

    BUSINESSWIRE

    Roivant Reports Positive Results from ADORING 2 Atopic Dermatitis PIII of VTAMA

    GLOBENEWSWIRE

    Proteovant to Present Data from Estrogen Receptor and IKZF2 Protein Degrader

    GLOBENEWSWIRE

    Roivant to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis

    GLOBENEWSWIRE

    Covant Therapeutics Announces the Formation of its Scientific Advisory Board

    GLOBENEWSWIRE

    Roivant founder Ramaswamy unveils `anti-woke` presidential bid

    FIERCE BIOTECH

    Roivant Sciences Announces Change to its Board of Directors

    GLOBENEWSWIRE

    Roivant Reports Financial Results for Q3 Ended December 31, 2022

    GLOBENEWSWIRE

    Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares

    GLOBENEWSWIRE

    Roivant, Vera seek $100M+ raises as they look to fund drug hopefuls

    ENDPTS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.